Second Department of Urology, Sismanoglio Hospital, Athens Medical School, Athens, Greece.
Department of Urology, Technical University Munich, Munich, Germany.
Eur Urol. 2015 Apr;67(4):750-63. doi: 10.1016/j.eururo.2014.10.029. Epub 2014 Nov 20.
An optimum metabolic evaluation strategy for urinary stone patients has not been clearly defined.
To evaluate the optimum strategy for metabolic stone evaluation and management to prevent recurrent urinary stones.
Several databases were searched to identify studies on the metabolic evaluation and prevention of stone recurrence in urolithiasis patients. Special interest was given to the level of evidence in the existing literature.
Reliable stone analysis and basic metabolic evaluation are highly recommended in all patients after stone passage (grade A). Every patient should be assigned to a low- or high-risk group for stone formation. It is highly recommended that low-risk stone formers follow general fluid and nutritional intake guidelines, as well as lifestyle-related preventative measures to reduce stone recurrences (grade A). High-risk stone formers should undergo specific metabolic evaluation with 24-h urine collection (grade A). More specifically, there is strong evidence to recommend pharmacological treatment of calcium oxalate stones in patients with specific abnormalities in urine composition (grades A and B). Treatment of calcium phosphate stones using thiazides is only highly recommended when hypercalciuria is present (grade A). In the presence of renal tubular acidosis (RTA), potassium citrate and/or thiazide are highly recommended based on the relative urinary risk factor (grade A or B). Recommendations for therapeutic measures for the remaining stone types are based on low evidence (grade C or B following panel consensus). Diagnostic and therapeutic algorithms are presented for all stone types based on the best level of existing evidence.
Metabolic stone evaluation is highly recommended to prevent stone recurrences.
In this report, we looked at how patients with urolithiasis should be evaluated and treated in order to prevent new stone formation. Stone type determination and specific blood and urine analysis are needed to guide patient treatment.
尚未明确界定尿石症患者的最佳代谢评估策略。
评估代谢性结石评估和管理的最佳策略,以预防复发性尿路结石。
检索了多个数据库,以确定有关尿石症患者代谢评估和预防结石复发的研究。特别关注现有文献中的证据水平。
强烈推荐所有结石排出后的患者进行可靠的结石分析和基本代谢评估(A级)。应将每位患者分为低风险或高风险结石形成组。强烈建议低风险结石形成者遵循一般液体和营养摄入指南以及与生活方式相关的预防措施,以降低结石复发率(A级)。强烈建议高风险结石形成者进行特定的代谢评估,包括 24 小时尿液收集(A级)。具体而言,有强有力的证据推荐对尿液成分存在特定异常的草酸钙结石患者进行药物治疗(A 级和 B 级)。当存在高钙尿症时,强烈推荐使用噻嗪类药物治疗磷酸钙结石(A级)。存在肾小管酸中毒(RTA)时,根据相对尿危险因素强烈推荐使用枸橼酸钾和/或噻嗪类药物(A级或 B 级)。基于低证据(根据专家组共识为 C 级或 B 级),推荐了治疗其余结石类型的治疗措施。基于现有最佳证据,为所有结石类型提出了诊断和治疗算法。
代谢性结石评估可有效预防结石复发。
在本报告中,我们研究了如何评估和治疗尿石症患者以预防新结石形成。需要确定结石类型并进行特定的血液和尿液分析,以指导患者治疗。